Morepen Labs net profit leaps over two-fold to Rs 19.36 crore in Q1
API sales revenue during the quarter grew by 44 percent to Rs 162.06 crore, the filing said.
New Delhi: Drug firm Morepen Laboratories on Monday reported over two-fold jump in its consolidated net profit at Rs 19.36 crore for the quarter ended June 30, 2020, mainly on account of robust sales in the active pharmaceutical ingredient (API) segment. The company had posted a net profit of Rs 7.65 crore in the corresponding period of the previous fiscal, Morepen Laboratories said in a filing to the BSE.
Consolidated total revenue stood at Rs 258.97 crore during the quarter under review. It was at Rs 203.26 crore in the same period a year ago, it added.
"API business of the company is doing exceedingly well and is gaining greater traction in the international markets, thanks to the highest standards of quality maintained by the company for the latest innovative products," Morepen Laboratories Chairman and MD Sushil Suri said.
API sales revenue during the quarter grew by 44 percent to Rs 162.06 crore, the filing said.
The company's board has approved an expansion plan involving an outlay of Rs 178 crore. This would substantially add to the company's API manufacturing capacity.
The expansion plan has already been cleared by the Himachal state government under a single window clearance scheme, it added.
Shares of Morepen Laboratories on Monday closed 2.39 percent higher at Rs 27.80 per scrip on the BSE.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.